CASI Pharmaceuticals, Inc.

CASI

KYG1933S1012

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-14 pm EDT			5-day change	1st Jan Change
3.11 ^USD	-4.60%		-10.37%	-56.56%

May. 15	Sector Update: Health Care Stocks Advance in Afternoon Trading	MT
May. 15	CASI Pharmaceuticals Gets FDA Clearance For Blood Disorder Study	MT

CASI Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2022

February 16, 2022 at 07:09 am EST

CASI Pharmaceuticals, Inc. provided revenue guidance for the year 2022. The company is targeting full-year 2022 revenue guidance of more than 30% growth over 2021 for EVOMELA.

Latest news about CASI Pharmaceuticals, Inc.

Sector Update: Health Care Stocks Advance in Afternoon Trading	May. 15	MT
CASI Pharmaceuticals Gets FDA Clearance For Blood Disorder Study	May. 15	MT
CASI Pharmaceuticals Receives FDA Clearance on the Investigational New Drug Application for CID-103 in Immune Thrombocytopenia	May. 15	CI
Earnings Flash (CASI) CASI PHARMACEUTICALS Posts Q1 Revenue $3.4M, vs. Street Est of $12M	May. 14	MT
CASI Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 14	CI
CASI Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Top Midday Gainers	Mar. 05	MT
Looming Employment Report, Powell Testimony Stifle US Equity Futures Pre-Bell	Mar. 05	MT
Rate Cut Uncertainty Pushes Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday	Mar. 05	MT
Top Premarket Gainers	Mar. 05	MT
CASI Pharmaceuticals Report Positive Interim Phase 1 Data for BI-1206 in the Treatment of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma in China	Mar. 05	CI
CASI Pharmaceuticals, Inc. and CASI Pharmaceuticals Co. Ltd Enter into Certain Agreement with Respect to the Renewal of the Exclusive Distribution Agreement with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd	Feb. 29	CI
Casi Pharmaceuticals Announces First Dose of Folotyn in China	Feb. 16	CI
CASI Pharmaceuticals, Inc. Announces Resignation of Fuqiang Zhang as Chief Commercial Officer	Feb. 12	CI
CASI Pharmaceuticals, Inc. Appoints of Mr. Huang Hai as the Global Chief Commercial Officer	Jan. 30	CI
CASI Pharmaceuticals, Inc. Enters into an Exclusive Distribution Agreement with China National Medicines Corporation Ltd	Dec. 08	CI
HC Wainwright Raises Price Target on CASI Pharmaceuticals to $12 From $10, Keeps Buy Rating	Nov. 15	MT
Earnings Flash (CASI) CASI PHARMACEUTICALS Posts Q3 Revenue $8.8M	Nov. 14	MT
CASI Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Earnings Flash (CASI) CASI PHARMACEUTICALS Posts Q2 Revenue $9.8M	23-08-11	MT
CASI Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
CASI Pharmaceuticals Acquires Intellectual Property Rights to Cleave Therapeutics' Drug Candidate CB-5339	23-07-20	MT
CASI Pharmaceuticals, Inc.(NasdaqCM:CASI) dropped from S&P TMI Index	23-06-20	CI
CASI Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-17	CI
Earnings Flash (CASI) CASI PHARMACEUTICALS Reports Q1 Revenue $8.3M	23-05-17	MT

Chart CASI Pharmaceuticals, Inc.

Duration

Period

More charts

CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing, and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. Its commercial product, EVOMELA, is an intravenous formulation of melphalan commercialized by Acrotech in the multiple myeloma treatment setting in the United States. Its pipeline products include CNCT19 (CD19 CAR-T), BI-1206 (anti- FcYRIIB antibody), CB-5339 (VCP/p97 inhibitor), CID-103 (Anti-CD38 Mab), Thiotepa, and Octreotide LAI. The Companyâs Food and Drug Administration (FDA)-approved generic products for the China market include Entecavir tablets, Tenofovir disoproxil fumarate (TDF) tablets, Cilostazol tablets-50mg, Cilostazol tablets-100mg, Ondansetron HCL tablets, and Tizanidine tablets.

Sector

Pharmaceuticals

Calendar

2024-08-08 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for CASI Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

3.11 USD

Average target price

6 USD

Spread / Average Target

+92.93%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
CASI PHARMACEUTICALS, INC.	-56.56%	40.4M
NOVO NORDISK A/S	+41.96%	630B
JOHNSON & JOHNSON	-7.15%	350B
MERCK & CO., INC.	+18.77%	328B
ABBVIE INC.	+8.79%	298B
ASTRAZENECA PLC	+18.02%	246B
ROCHE HOLDING AG	+1.27%	225B
NOVARTIS AG	+11.95%	218B
AMGEN INC.	+3.68%	160B
PFIZER, INC.	-4.38%	156B

Other Pharmaceuticals